Hiromasa Kurosaki
| Hiromasa Kurosaki | |
| Native name | 黒﨑弘正 |
|---|---|
| Born | 1971年2月14日（53歳） in Tokyo |
| 🏳️ Nationality | Japanese |
| 💼 Occupation | |
Hiromasa Kurosaki（黒﨑弘正Kurosaki Hiromasa、born 14 February 1971） is a Japanese medical doctor, a radiologist certified by the japanese college of radiology, and a nuclear medicine specialist certified by The Japanese Society of Nuclear Medicine.
Kurosaki is an expert in the treatment of cancer with bone metastasis. The radiopharmaceutical "Xofigo," which emits alpha particles, was approved in Japan in 2016 for the treatment of bone metastases in castration-resistant prostate cancer that does not respond to hormone therapy. Kurosaki was an early adopter of this treatment and has achieved significant therapeutic outcomes with it.
Kurosaki has already completed four clinical studies of Boron Neutron Capture Therapy (BNCT) in 2023 and is considering the fifth case in 2024. This constitutes the highest number of cases in BNCT treatment worldwide. Patients from around the globe seek his treatment, and he has extensive experience in treating numerous patients to date.
Kurosaki is known for having a cousin, Yosuke Nishijima, who was the only heavyweight competitor in Japan. He moved to Utsunomiya at the age of 4 and graduated from the Utsunomiya University Faculty of Education Affiliated Kindergarten through Junior High School. Among his classmates was MLB commentator Aki Inose.
Life[編集]
After graduating from Tochigi Prefectural Utsunomiya High School in March 1989, he enrolled in Gunma University's Faculty of Medicine. Influenced by the Olympic rower Norimasa Kurosaki, he was a member of the rowing club during his university years.
Career Development[編集]
Kurosaki spent the initial years of his career at the Department of Radiology at Gunma University, followed by experiences in multiple medical institutions such as Gunma Prefectural Cancer Center, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, and Toranomon Hospital, particularly excelling in Combined Hyperthermia and Radiotherapy for the Treatment of Cancer. From 2012, he served at the Tokyo Shinjuku Medical Center, as the department head from 2015 to 2021.
In 2021, he started working as the head of the Radiology Department at Edogawa Hospital. Edogawa Hospital, known for introducing the first Tomotherapy in the main island of Japan, and owning three units worldwide.
Career Development at Edogawa Hospital[編集]
Edogawa Hospital ranks sixth in Japan for the number of intensity-modulated radiation therapy cases in 2022. In July 2023, Kurosaki led the world's first treatment using an accelerator-based neutron capture therapy device for breast cancer. Additionally, he is actively involved in academic societies, serving as a director of the Japan Hyperthermia Society, the chairman of the 41st conference.
Organizations[編集]
Articles[編集]
This article "Hiromasa Kurosaki" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Hiromasa Kurosaki.
